Transaction DateRecipientSharesTypePriceValue
12th February 2021Gary L Crocker5,000Open or private purchase$7.47$37,342.00
11th February 2021Gary L Crocker1,604Open or private purchase$7.98$12,797.51
10th February 2021Gary L Crocker3,500Open or private purchase$7.64$26,756.80
1st December 2020Noah G. Levy12,417Open or private purchase$4.00$49,656.82
1st December 2020Noah G. Levy17,359Open or private purchase$4.00$69,420.38
24th November 2020Noah G. Levy40,278Open or private purchase$3.65$147,014.70
24th November 2020Noah G. Levy28,809Open or private purchase$3.65$105,152.85
12th November 2020Eric Andersen1,959Open or private purchase$3.65$7,150.35
12th November 2020Noah G. Levy23,556Open or private purchase$3.65$85,863.98
12th November 2020Noah G. Levy32,934Open or private purchase$3.65$120,047.72
Merrimack Pharmaceuticals
Merrimack Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 4/10.

Merrimack Pharmaceuticals is a clinical stage biopharmaceutical company. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993.

Ticker: MACK
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1274792
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $16 M (0%)
Assets, Current: $19 M (3%)
Other Assets, Noncurrent: $315 Th (-77%)
Assets: $20 M (-1%)
Accounts Payable, Current: $208 Th (-23%)
Accrued Liabilities, Current: $216 Th (-41%)
Liabilities, Current: $2 M (-15%)
Liabilities: $2 M (-15%)
Common Stock, Value, Issued: $1 M (0%)
Common Stock, Shares, Issued: $13 Th (0%)
Additional Paid in Capital, Common Stock: $558 M (0%)
Retained Earnings (Accumulated Deficit): $542 M (0%)
Stockholders' Equity (Parent): $17 M (0%)
Liabilities and Equity: $20 M (-1%)
Research and Development: $5 M (-57%)
General and Administrative Expenses: $1 M (-62%)
Operating Income/Loss: $1 M (20%)
Other Income, net: $21 Th (-68%)